Skip to main content

Table 1 Baseline differences between the included and excluded populations

From: Trying to identify who may benefit most from future vitamin D intervention trials: a post hoc analysis from the VITDAL-ICU study excluding the early deaths

  Included
N = 410
Excluded
N = 65
P value Deceased
< 7 days
N = 43
Discharged
< 7 days
N = 22
P value
Age, years 64 ± 15 67 ± 12 0.06 69 ± 11.7 64.2 ± 12.8 0.13
Body mass index 27.2 ± 5.2 27.1 ± 5.7 0.94 26.9 ± 5 27.5 ± 6.4 0.69
25-Hydroxyvitamin D, ng/ml 13.2 ± 4.6 13.4 ± 5 0.67 12.9 ± 4.8 14.4 ± 5.4 0.26
1,25-Dihydroxyvitamin D, pg/ml 42 (38–46) 47 (36–58) 0.36 29.3 ± 21.5 83.1 ± 56.2 < 0.01
Charlson Comorbidity Index 3 (2.8–3.2) 3.4 (2.9–3.9) 0.25 3.6 ± 2 2.9 ± 1.9 0.23
SAPS 2 32.7 ± 15.4 36.6 ± 15 0.06 39.4 ± 15 31 ± 14 0.04
TISS 38 ± 7.7 37 ± 8.8 0.36 41.3 ± 7.3 28.8 ± 4.6 < 0.01
Male/female gender, N/N 267/143 42/23 0.94 30/13 12/10 0.22
Chronic kidney disease, N (%) 113 (27.5) 21 (32.3) 0.43 18 (41.8) 3 (13.6) 0.02
Surgical/medical and neuro admission N/N 240/170 14/51 < 0.01 12/31 2/20 0.08
Chronic liver disease, N (%) 61 (14.9) 10 (15.4) 0.85 7 (16.3) 3 (13.6) 0.78
COPD, N (%) 77 (18.8) 10 (15.4) 0.61 8 (18.6) 2 (9.1) 0.31
Ischemic heart disease—chronic heart failure, N (%) 229 (55.8) 26 (40) 0.59 26 (60.5) 8 (36.4) 0.07
Malignant disease, N (%) 34 (8.3) 4 (6.2) 0.55 2 (4.7) 2 (9.1) 0.48
Mechanical ventilation at enrollment, N (%) 268 (65.0) 34 (52.0) 0.09 34 (79.1) 0 < 0.01
Use of vasopressor at enrollment, N (%) 203 (49.5) 32 (49.2) 0.44 32 (74.4) 0 < 0.01
  1. Continuous variables are presented as value ± standard deviation or median (95% confidence interval), binary variables as number, and percentage
  2. *Responder to vitamin D treatment: patients with an increase of 25-hydroxyvitamin D plasma levels on day 3 after enrollment of at least 10 ng/ml
  3. SAPS 2 simplified acute physiology score 2, TISS Therapeutic intervention scoring system